For research use only
| Product Infomation | |
| Product Name | SEL120-34A HCl |
|---|---|
| CAS No. | 1609452-30-3 |
| Molecular Weight | 450.59
|
| Formula | C₁₅H₁₈Br₂N₄.HCl |
| SMILES | CC1=C(Br)C(Br)=C2C3=C1N=C(N4CCNCC4)N3CCC2.[x HCl] |
| Stock status | Instock |
Online consultation: 
Product description:
| Description | SEL120-34A HCl is a potent, selective, orally available, ATP-competitive CDK8 inhibitor, with IC50s of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively, with antitumor activity.
| |
| IC50 & Target | CDK8/CycC, 4.4 nM (IC50) | |
| In Vitro | SEL120-34A HCl is a selective, ATP-competitive CDK8 inhibitor, with IC50 of 4.4 nM and 10.4 nM for CDK8/CycC and CDK19/CycC, respectively. SEL120-34A HCl shows no obvious inhibition on CDK1, 2, 4, 6, 5, 7, and only weakly suppresses CDK9 (IC50, 1070 nM). SEL120-34A HCl is active against a panel of AML cell lines (GI50<1 μM), such as SKNO-1, KG-1, HEL-60, MOLM-16, MV-4-11, OciAML-2, MOLM-6 and OciAML-3 cells, consistent with the effective inhibition range of STAT1 S727 and STAT5 S726[1]. | |
| Powder | -20°C | 3 years |
| 4°C | 2 years | |
| In solvent | -80°C | 6 months |
| -20°C | 1 month | |
Peferences:
[1]. Rzymski T, et al. SEL120-34A is a novel CDK8 inhibitor active in AML cells with high levels of serine phosphorylation of STAT1 and STAT5 transactivation domains. Oncotarget. 2017 May 16;8(20):33779-33795.
